In contrast, LAGλ-1 tumors, originating from a bortezomib-refractory MM patient, did not show a significant reduction in tumor growth even with high dose (0.24 mg/kg) IFNα treatment (Fig 1E). This evidence concerns the gene IFNA2 and Miyoshi myopathy.